ライフサイエンスコーパス: tumor vaccine

1 ability of radiation to generate an in situ tumor vaccine.

2 eveloped a novel GM-CSF-secreting pancreatic tumor vaccine.

3 pilot clinical trial using Ag-pulsed DC as a tumor vaccine.

4 cells pulsed with recombinant mouse PAP as a tumor vaccine.

5 inant virus to serve as a safe and effective tumor vaccine.

6 roved formulation of chaperone protein-based tumor vaccine.

7 94 (GRP94/gp96) has shown great promise as a tumor vaccine.

8 opyranosyl lipid A (GLA), using a whole-cell tumor vaccine.

9 h the murine anti-idiotype antibody 3H1 as a tumor vaccine.

10 ion therapy's ability to generate an in situ tumor vaccine.

11 linical trial designs for the development of tumor vaccines.

12 e important implications for the crafting of tumor vaccines.

13 TCR complex are significantly more potent as tumor vaccines.

14 compatibility antigens (mHAgs) in whole-cell tumor vaccines.

15 od to enhance the activity of nonimmunogenic tumor vaccines.

16 th metastatic melanoma who were administered tumor vaccines.

17 asis for new generations of antigen-specific tumor vaccines.

18 may provide a new avenue for development of tumor vaccines.

19 act or tumor RNA, and cytokine gene-modified tumor vaccines.

20 d suggests it may enhance the development of tumor vaccines.

21 roblasts as vehicles to deliver cytokines in tumor vaccines.

22 orspecific CTLs may lead to epitope-specific tumor vaccines.

23 ation, therefore acting as potential in situ tumor vaccines.

24 ancer cells and examined their properties as tumor vaccines.

25 tive strategy for increasing the efficacy of tumor vaccines.

26 or the optimization of antigen-specific anti-tumor vaccines.

27 vel agents such as targeted therapeutics and tumor vaccines.

28 g the possibility of generating in situ anti-tumor vaccines.

29 an improve the clinical efficacy of DC-based tumor vaccines.

30 n targeted for the development of colorectal tumor vaccines.

31 en-presenting cells with a potential role in tumor vaccines.

32 age tumors, and may help improve therapeutic tumor vaccines.

33 fort to increase the therapeutic efficacy of tumor vaccines.

34 herapy with agents such as interleukin-2 and tumor vaccines.

35 tilized in the design of novel peptide-based tumor vaccines.

36 gests a novel approach to the development of tumor vaccines.

37 uggest that using cell-associated dsRNA as a tumor vaccine adjuvant may be a suitable strategy for en

38 We conclude that tumor vaccines administered after allogeneic BMT can aug

39 gate recombinant Listeria monocytogenes as a tumor vaccine against s.c. and intracerebral challenges

40 neic, HER2-positive, GM-CSF-secreting breast tumor vaccine alone or with CY and DOX is safe and induc

41 In addition, tumor vaccines alone have a limited potential for the tr

42 In addition, a mesothelin tumor vaccine and a mesothelin- chimeric antigen recepto

43 ical quality of a recombinant poxvirus-based tumor vaccine and that the use of promoters capable of d

44 efore likely to serve as a strategy for both tumor vaccines and adoptive immunotherapy of cancer.

45 Tumor vaccines and cellular immunotherapies could synerg

46 Tumor vaccines and cellular immunotherapies enhanced OS

47 re are major differences between therapeutic tumor vaccines and chemotherapeutic agents that have imp

48 be generally used to improve the efficacy of tumor vaccines and immunotherapies.

49 ons in the induction of cellular immunity by tumor vaccines and may have important implications for f

50 relevant to the clinical evaluation of human tumor vaccines and suggests that cell-mediated cytolytic

51 vileged" CNS would pose to cytokine-assisted tumor vaccines and what cytokines would be most efficaci

52 apies including second-generation retinoids, tumor vaccines, and new modes of drug delivery with impr

53 In the ex vivo tumor vaccine approach, B16 melanoma cells, transduced i

54 Allogeneic GM-CSF-secreting tumor vaccines are safe in patients with pancreatic aden

55 c, phase I/II trials support the notion that tumor vaccines are safe.

56 an parental tumor, and CIITA expression in a tumor vaccine assay lacked efficacy.

57 ntigens are chosen as primary candidates for tumor vaccine because of their expression on multiple li

58 e have developed an in vivo HSP-suicide gene tumor vaccine by generating a recombinant replication-de

59 to the tumor can convert it into an in situ tumor vaccine by inducing release of antigens during can

60 We generated a cellular tumor vaccine by pulsing dendritic cells with enriched m

61 esentation and for developing more effective tumor vaccines by silencing the critical brake in antige

62 Tumor vaccines can be used to induce immunologically spe

63 colony-stimulating factor (GM-CSF)-secreting tumor vaccines can cure established tumors in the mouse,

64 Although tumor vaccines can increase the number of tumor-specific

65 al studies have demonstrated that autologous tumor vaccines can induce relatively specific tumor-reac

66 r histocompatibility antigens (mHAgs) on the tumor vaccine cells.

67 ndritic cells and macrophages among prostate tumor vaccine cells.

68 colony-stimulating factor (GM-CSF)-secreting tumor vaccine combinations demonstrate therapeutic syner

69 en seen in colon cancer patients receiving a tumor vaccine comprised of this altered peptide.

70 IL-2- and CD40L-expressing recipient-derived tumor vaccine consisting of leukemic blasts admixed with

71 Cell-based tumor vaccines, consisting of MHC class I+ tumor cells e

72 Lymph nodes (LN) draining both D5 and D5-Kd tumor vaccines contained increased numbers of cells with

73 pressing Line 1 cells served as an effective tumor vaccine, demonstrating that CD86 is effective in i

74 nd enhancement of this process is a focus of tumor vaccine design.

75 ansplantation, but also for autoimmunity and tumor vaccine design.

76 peutic CD8(+) T cells by a GM-CSF-transduced tumor vaccine did not require CD40 and CD40L interaction

77 ils to generate therapeutic T cells from the tumor vaccine-draining lymph nodes (TVDLN) in our adopti

78 or-specific T cells preferentially expand in tumor vaccine-draining lymph nodes after a melanoma vacc

79 hat priming of therapeutic CD8(+) T cells in tumor vaccine-draining lymph nodes of mice vaccinated wi

80 generated D5-specific effector T cells from tumor vaccine-draining lymph nodes of wild type (wt), pe

81 resensitized CD25-depleted T cells increased tumor vaccine efficacy.

82 e responses, and LATS1/2 deficiency enhances tumor vaccine efficacy.

83 fic mAb with a neu-targeted GM-CSF-secreting tumor vaccine enhanced induction of neu-specific CD8(+)

84 pproach gaining increasing popularity in the tumor vaccine field is to immunize cancer patients with

85 recognized by T cells has revolutionized the tumor vaccine field.

86 modified tumor cells can be used as a potent tumor vaccine for both autologous and HLA class I-matche

87 op an improved formulation of HSP70.PC-based tumor vaccine for patient use, we extracted HSP70.PC-F f

88 encoding murine PSCA (DCLV-PSCA) as a novel tumor vaccine for prostate cancer in mouse models.

89 vity of an autologous GM-CSF gene-transduced tumor vaccine for RCC patients.

90 lications for the use of GM-CSF-G250 FP as a tumor vaccine for the treatment of patients with advance

91 tope, thereby enhancing its potential use in tumor vaccines for appropriately selected cancer patient

92 laboratory data stress the vast potential of tumor vaccines for the treatment of cancer.

93 he formation of immune complexes that target tumor vaccines for uptake by APCs, via the interaction o

94 f animals receiving the irradiated wild-type tumor vaccine grew large tumors, and 50% died.

95 or antigens to antigen presenting cells, HSP tumor vaccine has been tested in clinical trials.

96 vectors (PNVs)) as potential carriers for DC tumor vaccines has not been presented before.

97 f the allogeneic environment on responses to tumor vaccines has not been well characterized.

98 omising new therapeutic approaches including tumor vaccine have been explored.

99 olony-stimulating factor (GM-CSF) -secreting tumor vaccines have demonstrated bioactivity but may be

100 Dendritic cell (DC)-based tumor vaccines have only achieved limited clinical effic

101 Tumor vaccines have shown promise in early clinical tria

102 e immune responses and limit the efficacy of tumor vaccines; however, it remains a challenge to selec

103 effective than other modes of creating whole tumor vaccines, i.e., UV or ionizing irradiation, and un

104 summarizes the use of adoptive cell therapy, tumor vaccines, immune checkpoint inhibitors, and combin

105 of delayed-type hypersensitivity to a model tumor vaccine in mice and enhanced the Ag-presenting fun

106 e to the use of the in vivo HSP/suicide gene tumor vaccine in therapy for human solid tumors.

107 ll function in vitro and in the context of a tumor vaccine in vivo.

108 We have developed a tumor vaccine in which patient-derived myeloma cells are

109 mor immunity has reshaped the development of tumor vaccines in clinical medicine.

110 ggested that the immunogenicity of autologus tumor vaccines in humans may be augmented by engineering

111 major implications for the implementation of tumor vaccines in humans.

112 ng doses of chemotherapy in combination with tumor vaccines in patients with cancer.

113 DC-based or protein-based tumor vaccines, in combination with B7-H1 blockade, indu

114 to turn a patient's tumor into an endogenous tumor vaccine; in this context of RF ablation-triggered

115 factor (GM-CSF) gene-transduced, irradiated tumor vaccines induce potent, T-cell-mediated antitumor

116 n IL-12-transduced but not a mock-transduced tumor vaccine induces systemic tumor immunity in anti-CD

117 ogical endpoints in early clinical trials of tumor vaccines, investigate the design implications of a

118 , as such, has served as the major model for tumor vaccine investigation in both the laboratory and t

119 ses after the administration of three potent tumor vaccines: irradiated MCA 105, MCA 105 admixed with

120 y of tumor-associated antigens in autologous tumor vaccines is limited because of insufficient uptake

121 The therapeutic activity of tumor vaccines is limited by the sheer physical burden o

122 A major prerequisite for the success of tumor vaccines is their effective uptake by antigen-pres

123 acilitating effective Ag presentation by the tumor vaccine itself.

124 hat immunization of BMT donors with cellular tumor vaccines leads to curative GVT but induces unaccep

125 icate that genetically engineered autologous tumor vaccines may be capable of inducing significant an

126 ulocyte-macrophage colony-stimulating factor tumor vaccines may generate a diverse repertoire of tumo

127 mmune responses, this HSP-mediated oncolytic tumor vaccine might become a universally applicable, per

128 f helper epitopes from foreign antigens into tumor vaccines might enhance the immunogenicity of DNA v

129 In a therapeutic tumor vaccine model, immunization with the melanoma pept

130 ection from tumor engraftment in a syngeneic tumor vaccine model, inhibited neutrophil extravasation,

131 n situ, to quantify APC delivery to LNs in a tumor vaccine model.

132 In tumor vaccine models, drugs that induce cell surface cal

133 ression, Sp17 may be an excellent target for tumor vaccine of MM.

134 Tumor vaccines offer the potential for preventing cancer

135 -cell activity might improve the efficacy of tumor vaccines or the immunotherapy of cancer.

136 Cellular therapies outperformed tumor vaccines (OS as HR: P = .005, month difference: P

137 murine models, transgenic chemokine-cytokine tumor vaccines overcome many of the limitations of singl

138 mmunization of donors with recipient-derived tumor vaccines preferentially induces tumor-specific T-c

139 ith autologous, GM-CSF-secreting, irradiated tumor vaccines prepared from ex vivo retroviral transduc

140 Tumor vaccines produced using HSV amplicon-mediated gene

141 oluble Flt3-L, administration of Flt3-L as a tumor vaccine protected mice from a subsequent challenge

142 therefore have implications in the APC-based tumor vaccine protocol design.

143 we developed a novel HSP-mediated oncolytic tumor vaccine, referred to as HOT vaccine, by combining

144 e of their having sufficient immunogenicity, tumor vaccines remain largely ineffective.

145 intensive effort, the antitumor efficacy of tumor vaccines remains limited in treating established t

146 Tumor vaccines represent a promising therapeutic approac

147 DC-based tumor vaccine research has largely focused on enhancing

148 reased 1.9-fold and 16.4-fold by Flt3L or DC tumor vaccines, respectively.

149 These results suggest that whereas B7-1+ tumor vaccines result in some degree of direct presentat

150 sentation is difficult to achieve by current tumor vaccine strategies.

151 a suitable disease for genetically modified tumor vaccine strategies.

152 e have developed a molecular chaperone-based tumor vaccine that reverses the immune tolerance of canc

153 unization of cancer patients with autologous tumor vaccines that are engineered to express alpha-gal

154 Reports of novel developments in tumor vaccines that have appeared in the year ending May

155 One way to improve current tumor vaccines that mainly induce CTLs would be to activ

156 ld be useful for the development of DC-based tumor vaccine therapies.

157 rovide the foundation for the development of tumor vaccines through the use of cytotoxic T cells to i

158 was to examine whether DKK1 can be used as a tumor vaccine to elicit DKK1-specific immunity that can

159 ulfilling this requirement should be used as tumor vaccines, together with DC maturating agents, espe

160 s-priming of therapeutic CD8(+) T cells by a tumor vaccine transduced with GM-CSF requires TNFR, IL-1

161 survived, while all nontreated controls and tumor vaccine-treated rats died within 40 days.

162 of sulfhydryl groups may also occur in vivo, tumor vaccines using this or other cysteine-containing p

163 ytotoxic chemotherapy can be integrated with tumor vaccines using unique doses and schedules to break

164 In this study, the efficacy of 3H1 as a tumor vaccine was evaluated in a murine tumor model.

165 t with the in vitro data, only DC/irradiated tumor vaccines were effective in preventing or delaying

166 Tumor vaccines were produced by brief (20 minutes) expos

167 destruction in situ may provide a polyvalent tumor vaccine without a requirement for knowledge of the

168 d B16 vaccines enhanced clinical activity of tumor vaccines without exacerbating GVHD.

169 ines up to the feasible limits of autologous tumor vaccine yield.